

**Performance of top companies in May'24**

Company	MAT growth (%)	May'24 (%)
IPM	7.4	9.8
Abbott*	7.9	9.2
Ajanta	9.0	12.3
Alembic	3.1	6.8
Alkem*	5.8	8.8
Cipla	7.3	10.2
Dr Reddys	7.1	9.2
Emcure*	5.1	7.7
Eris	8.9	10.6
Glaxo	0.2	3.8
Glenmark	10.2	18.9
Intas	11.9	9.6
Ipca	10.6	5.7
Jb Chemical*	10.2	13.1
Lupin	6.5	9.9
Macleods	9.4	15.9
Mankind	7.8	11.1
PGHL	0.0	12.2
Sun*	8.5	7.5
Torrent	8.2	9.3
Zydus*	5.9	11.8

**Uptrend in IPM growth continues for second month**

- The Indian pharma market (IPM) grew 9.8% YoY in May'24 (vs. 8.9% in Apr'24 and 10.2% in May'23). Chronic category remained the key growth driver, supported by recovery in Acute therapies.
- Cardiac/Gastro-intestinal therapies registered healthy YoY growth of 12.0% each. Respiratory/Gynae/Neuro/Ant-diabetic underperformed IPM by 500bp/300bp/300bp/200bp in May'24.
- For the 12 months ending in MAT May'24, IPM grew 7.4% YoY. This growth was led by price/new launches, which contributed 4.1%/2.9% YoY to overall growth over the same period. Volume growth remained muted on MAT basis.
- Among the top 10 brands, Electral/PAN/LIV-52 registered growth of 28%/19%/17% YoY to INR720m/INR590m/INR620m in May'24.
- Although Anti-diabetic segments registered growth in May'24, key brands, like Mixtrad (INR710m)/Glycomet-GP (INR700m)/Novomix (INR320m), declined 4%/1%/11% YoY in May'24.

**Glenmark/Macleods/JB Chemicals outperform in May'24**

- In May'24, among the top-20 pharma companies, Glenmark (up 18.9% YoY), Macleods (up 15.9% YoY), and JB Chemicals (up 13.1% YoY) recorded notably higher growth rates than IPM.
- Glenmark outperformed IPM, led by strong performance in almost all therapies. Particularly, cardiac therapy registered 26.8% YoY growth in May'24.
- Macleods outperformed IPM, led by double-digit growth in all key therapies.
- JB Chemicals outperformed IPM with Cardiac/Gynaec/Derma posting a growth of 23.9%/26.5%/28.8% YoY in May'24, which was offset by an 18% YoY decline in ophthal therapy.
- Sanofi reported industry-leading volume growth of 9.4% YoY on the MAT basis. Macleods Pharma registered the highest price hike of 7.6% YoY on the MAT basis. Eris posted the highest growth in new launches (up 10.3% YoY).

**Cardiac/Gastro/Urology/Vaccines led YoY growth on MAT basis**

- On the MAT basis, the industry reported 7.4% growth YoY.
- Cardiac/Neuro/Ophthal/Gastro grew 12.4%/12.4%/12.4%/12.7% YoY.
- Respiratory/Gynae/Neuro/Anti-diabetic sales underperformed IPM by growing at 0.6%/6.5%/8.3%/6.3%, hurting overall growth.
- For seven consecutive months, Chronic therapy has outperformed acute therapy. Acute's share in overall IPM stood at 62% for MAT May'24, with YoY growth of 5.9%. The chronic segment (38% of IPM) grew 9.8% YoY.

**India and MNC pharma both posted growth for two consecutive months**

- As of May'24, Indian pharma companies hold a majority share of 83% in IPM, while the remaining is held by multi-national pharma companies (MNCs).
- After a strong decline in Mar'24, both Indian and MNCs have registered strong growth for two consecutive months.
- In May'24, among MNCs, Sanofi (up 12.2% YoY) outperformed IPM, supported by superior growth in key therapies. Glaxo (up 3.8% YoY) underperformed IPM owing to subdued performance in Derma/Anti-infective/Pain therapies.


**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Akash Manish Dobhada - Research Analyst** (Akash.Dobhada@motilaloswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**


Motilal Oswal research is available on [www.motilaloswal.com](http://www.motilaloswal.com)/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

**Exhibit 1: IPM witnessed 10% YoY growth in May'24**




Source: MOFSL, IQVIA

**Exhibit 2: Acute and chronic therapies registered YoY growth of 11%/9% in May'24**



Source: MOFSL, IQVIA

**Exhibit 3: Both Indian firms as well as MNCs saw healthy YoY growth in May'24**



Source: MOFSL, IQVIA

## Indian Pharma Market – May'24

Exhibit 4: Performance of top companies in May'24 - (INR b)

Company	MAT May'24 value	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month May'24
				Aug'22	Nov'22	Feb'23	May'23	Aug'23	Nov'23	Feb'24	May'24	
IPM	2,194	100	7.4	10.8	8.1	13.3	13.8	6.0	9.6	7.1	6.7	9.8
Sun Pharma	170	7.8	8.5	15.6	10.0	13.7	10.6	7.0	10.9	7.5	8.8	7.5
Abbott	136	6.2	7.9	14.0	7.6	12.8	13.6	6.3	10.9	8.3	6.3	9.2
Cipla	119	5.4	7.3	11.7	9.0	14.6	17.6	5.1	8.2	9.0	6.7	10.2
Mankind	98	4.4	7.8	11.1	10.3	22.2	21.1	3.9	8.6	9.4	9.0	11.1
Alkem	88	4.0	5.8	16.7	12.7	19.1	17.0	3.7	10.9	5.3	3.2	8.8
Lupin	435	2.0	5.1	6.0	4.1	12.4	10.5	4.8	6.7	5.2	3.8	7.7
Intas Pharma	78	3.6	11.9	17.6	15.1	16.9	14.7	11.1	13.1	12.8	10.6	9.6
Torrent	75	3.4	8.2	17.1	10.5	15.9	10.6	7.3	9.8	7.5	8.0	9.3
Macleods Pharma	74	3.4	9.4	16.4	10.1	20.2	18.5	7.8	13.0	6.9	9.6	15.9
Dr. Reddys	63	2.9	7.1	5.6	5.0	5.9	10.1	4.9	7.5	7.1	9.0	9.2
Zydus	63	2.8	5.9	10.4	8.3	11.1	12.7	5.0	6.5	5.1	6.9	11.8
GSK	52	2.4	0.2	7.3	6.5	11.0	12.1	-2.2	2.5	0.1	0.4	3.8
Glenmark	46	2.1	10.2	7.8	9.9	15.5	14.2	5.3	10.0	9.6	15.9	18.9
Ipca	43	2.0	10.6	23.0	8.9	13.5	17.5	7.8	15.9	12.3	6.5	5.7
Alembic	32	1.5	3.1	10.6	8.6	13.6	18.3	1.5	8.1	1.0	1.6	6.8
Eris Lifesciences	23	1.1	8.9	9.5	6.0	10.3	8.0	7.2	7.6	9.5	11.2	10.6
Jb Chemicals	25	1.1	10.2	27.8	37.3	39.2	18.4	9.9	9.6	10.6	10.8	13.1
Ajanta	17	0.8	9.0	14.4	15.2	19.0	14.6	11.5	6.3	8.0	10.4	12.3

Source: IQVIA, MOFSL

Exhibit 5: Performance of top therapies in May'24 - (INR b)

Company	MAT May'24 value	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month May'24
				Aug'22	Nov'22	Feb'23	May'23	Aug'23	Nov'23	Feb'24	May'24	
IPM	2,194	100.0	7.4	12.6	11.6	0.6	13.8	6.0	9.6	7.1	6.7	9.8
Cardiac	276	12.6	10.5	7.4	5.6	6.2	11.4	10.0	9.1	11.1	12.0	12.4
Anti-Infectives	245	11.2	3.2	21.1	38.0	-0.5	27.3	-2.7	13.0	0.9	0.7	9.5
Gastro Intestinal	233	10.6	8.2	24.1	-3.4	-8.5	8.7	6.3	11.1	7.3	8.2	12.4
Anti Diabetic	194	8.8	6.3	9.0	1.5	-1.3	7.4	5.3	5.4	7.8	6.8	7.6
Respiratory	179	8.1	0.6	-12.7	47.5	35.3	30.1	-5.1	9.4	-0.9	-2.2	4.7
Pain / Analgesics	175	8.0	7.2	20.0	14.2	-5.4	16.0	6.1	9.9	7.3	5.6	9.5
Vitamins/Minerals/Nutrients	172	7.8	7.7	21.3	5.5	-8.8	9.1	6.5	9.4	7.5	7.4	9.9
Derma	151	6.9	6.7	12.9	14.4	-2.4	8.0	7.3	2.8	7.6	9.4	9.9
Neuro / Cns	131	6.0	8.3	10.9	4.6	1.8	10.5	7.7	9.4	8.1	8.0	7.2
Gynaec.	110	5.0	6.5	21.1	-1.3	-6.5	7.1	7.5	7.0	7.1	4.5	6.6
Antineoplast/Immunomodulator	55	2.5	22.8	20.6	5.9	3.4	23.5	23.0	27.6	24.2	17.1	18.8
Ophthal / Otologicals	44	2.0	8.0	16.0	4.7	1.5	10.1	22.8	1.7	3.2	4.7	6.1
Urology	47	2.2	13.5	14.8	7.8	3.1	15.6	14.6	12.5	14.5	12.5	12.4
Hormones	34	1.5	6.5	12.3	16.2	7.5	16.9	7.3	8.9	4.8	5.1	7.5


Source: IQVIA, MOFSL

Exhibit 6: Among therapies, Cardiac/Gastro/VMN/Derma registered double-digit growth in May'24

Therapies	May'24	Value (INR b)	May'23	Jun'23	Jul'23	Aug'23	Sep'23	Oct'23	Nov'23	Dec'23	Jan'24	Feb'24	Mar'24	Apr'24	May'24
	Value (INR b)		May'23	Jun'23	Jul'23	Aug'23	Sep'23	Oct'23	Nov'23	Dec'23	Jan'24	Feb'24	Mar'24	Apr'24	May'24
IPM	189	10.0	4.0	6.0	6.0	9.0	17.0	4.0	5.0	8.0	8.0	1.0	9	10	
Cardiac	25	12	8	11	9	8	13	5	8	12	13	8	15	12	
Anti-Infective	19	8	-2	-5	-3	12	23	3	1	2	-1	-7	1	9	
Gastro	22	5	3	7	8	11	18	5	6	9	7	1	11	12	
Anti Diabetic	17	10	6	6	5	4	10	2	5	9	9	2	10	8	
Pain	15	10	5	6	5	10	17	3	5	9	8	1	6	9	
VMN	16	7	4	7	7	7	19	2	5	8	9	2	9	10	
Respiratory	12	9	-6	-7	-4	9	16	3	-2	1	-2	-8	-1	5	
Derma	13	11	8	8	6	3	8	-2	5	7	10	6	12	10	
Neuro	12	11	6	9	7	8	15	6	6	8	10	5.8	11	7	
Gynae	10	8	4	10	7	5	14	0	5	7	8	-0.3	7	7	
Ophthal	4	19	13	16	15	1	18	8	11	16	17	9	16	12	
Urology	189	10.0	4.0	6.0	6.0	9.0	17.0	4.0	5.0	8.0	8.0	1.0	9	10	

Note: VMN: Vitamin/Minerals/Nutrients; Source: IQVIA, MOFSL

Exhibit 7: Acute as a percentage of total sales and growth rate on MAT basis in May'24



Source: MOFSL, IQVIA



## Sun Pharma

Secondary sales grew 7.5% YoY in May'24 vs. 11.4% in Apr'24. Rosuvas, Sompraz-D, Moxclav outperformed among top 10 brands for May'24.

Anti-infective therapy remains a drag on overall growth. While Pain/Anti-diabetic registered double digit growth

Growth spread across volume, new launches, and price hikes for MAT May'24.

### Exhibit 8: Top 10 drugs

Drug	Therapy	MAT May'24			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	May'24
<b>Total</b>		<b>1,70,232</b>	<b>8.5</b>	<b>100.0</b>	<b>8.8</b>	<b>7.5</b>
Rosuvas	Cardiac	4,486	22.2	31.1	24.6	24.7
Levipil	Nuro/CNS	4,103	11.7	37.6	9.6	9.0
Volini	Pain / Analgesics	3,433	0.4	33.7	-1.7	-3.8
Gemer	Anti Diabetic	3,276	1.8	9.7	-4.7	-6.4
Susten	Gynae	2,946	5.9	32.7	4.7	2.9
Pantocid	Gastro Intestinal	2,918	8.9	20.8	8.6	11.6
Pantocid-D	Gastro Intestinal	2,685	7.6	16.4	8.6	5.7
Montek-Lc	Respiratory	2,406	1.3	18.8	-9.1	-7.2
Sompraz-D	Gastro Intestinal	2,362	19.1	28.7	20.1	14.5
Moxclav	Anti-Infectives	2,316	0.4	5.1	20.9	15.5

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 9: Therapy mix (%)

Total	Share	MAT growth (%)	3M*	May'24
	100.0	8.5	8.8	7.5
Neuro / Cns	17.5	10.0	10.1	8.1
Cardiac	17.0	8.9	8.6	7.3
Gastro Intestinal	13.1	9.9	9.2	8.2
Anti-Infective	8.7	2.0	4.6	5.0
Pain / Analgesics	7.8	12.3	15.5	13.0
Anti-Diabetic	7.4	12.6	13.8	10.4


Source: IQVIA, MOFSL

### Exhibit 10: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 11: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL

Cipla

Cipla

**Exhibit 12: Top 10 drugs**

Drug	Therapy	MAT May'24			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	May'24
<b>Total</b>		<b>1,18,628</b>	<b>7.3</b>	<b>100.0</b>	<b>6.7</b>	<b>10.2</b>
Foracort	Respiratory	8,802	16.9	60.7	9.3	9.1
Duolin	Respiratory	5,141	10.5	84.7	16.1	21.5
Budecort	Respiratory	4,783	11.2	82.7	8.8	18.6
Seroflo	Respiratory	3,031	4.3	72.8	4.2	4.5
Asthalin	Respiratory	2,911	3.5	99.3	6.4	11.6
Montair-Lc	Anti-Infectives	2,875	-0.8	18.2	4.9	10.9
Dytor	Cardiac	2,810	19.2	83.8	19.2	23.8
Ibugesic Plus	Anti-Infectives	2,358	13.2	66.0	7.8	15.9
Azee	Pain / Analgesics	2,313	-7.7	17.7	-7.6	2.0
Aerocort	Respiratory	2,218	5.9	95.0	6.0	12.9

\*Three-months: Mar-May'24

Source: IQVIA, MOFSL

Secondary sales grew 10.2% YoY in May'24 vs. 8.3% YoY in Apr'24. Duolin, Budecort, and Dytor exhibited healthy YoY growth in May'24.

Except Anti-diabetic, all the therapies registered double-digit growth in May'24.


Price/Volume/New launches led overall growth for MAT May'24 basis.

**Exhibit 13: Therapy mix (%)**

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>7.3</b>	<b>6.7</b>	<b>10.2</b>
Respiratory	37.5	9.1	8.0	11.5
Anti-Infectives	14.0	2.5	4.5	11.5
Cardiac	11.5	11.6	10.5	12.0
Anti-Diabetic	5.6	1.5	6.7	7.5
Gastro Intestinal	5.4	0.1	8.5	16.9
Urology	4.7	14.6	13.8	18.0


Source: IQVIA, MOFSL

**Exhibit 14: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 15: Growth distribution (%) (MAT May'24)**



Source: IQVIA, MOFSL



## Zydus Lifesciences

Zydus's secondary sales grew 11.8% YoY in May'24 vs. 10.6% in Apr'24. Lipaglyn/Vivitra were strong outperformers among top 10 brands for May'24.

### Exhibit 16: Top 10 drugs

Drug	Therapy	Value (INR m)	Growth (%)	MAT May'24		Growth (%)
				Market share (%)	Last 3M	
<b>Total</b>		<b>62,521</b>	<b>5.9</b>	<b>100.0</b>	<b>6.9</b>	<b>11.8</b>
Deriphyllin	Respiratory	2,140	-0.1	99.6	-5.4	2.4
Atorva	Cardiac	1,636	-9.4	18.8	-8.6	-3.3
Thrombophob	Cardiac	1,624	13.8	93.3	5.0	3.8
Lipaglyn	Anti-Diabetic	1,461	31.5	65.6	36.9	66.1
Amicin	Cardiac	1,403	10.6	17.2	1.8	16.5
Formonide	Respiratory	1,181	1.7	8.1	-1.9	0.3
Skinlite	Derma	1,128	-9.3	33.9	0.5	-3.2
Monotax	Antineoplast	1,063	21.7	6.5	20.9	48.9
Dexona	Anti-Infectives	1049	-3.4	68.2	-10.8	-1.1
Vivitra	Others	1011	34.8	26.3	49.8	21.3

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 17: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100</b>	<b>5.9</b>	<b>6.9</b>	<b>11.8</b>
Respiratory	14.1	3.4	1.2	6.4
Cardiac	13.3	3.7	7.2	16.1
Anti-Infectives	12.9	8.4	11.4	25.9
Gastro Intestinal	9.9	-1.3	2.3	6.7
Pain / Analgesics	7.9	9.0	5.0	6.2
Gynaec.	7.1	2.8	5.0	2.7

Source: IQVIA, MOFSL

### Exhibit 18: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 19: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Alkem

Secondary sales grew 8.8% YoY in May'24 vs. 6.6% in Apr'24. Pan/Clavam/Pan-D/Pipzo have shown robust growth despite the large scale of these brands in May'24.

Gastro/VMN outperformed the IPM led the growth in May'24.

Price/new launches contributed to overall YoY growth on MAT basis.

### Exhibit 20: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>87,912</b>	<b>5.8</b>	<b>100</b>	<b>3.2</b>
Pan	Gastro Intestinal	6,287	13.0	44.4	13.5
Clavam	Anti-Infectives	6,027	-1.3	14.0	7.4
Pan-D	Gastro Intestinal	5,460	16.1	33.3	17.4
Taxim-O	Anti-Infectives	3,178	0.0	18.3	0.5
A To Z Ns	VMN	2,913	7.9	11.8	11.3
Xone	Anti-Infectives	2,687	4.4	16.4	-9.0
Pipzo	Anti-Infectives	2,044	25.7	23.1	16.2
Uprise-D3	VMN	1,820	31.4	17.1	19.2
Gemcal	VMN	1,817	-1.3	18.7	1.8
Taxim	VMN	1,746	-7.5	80.3	-13.1

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 21: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>5.8</b>	<b>3.2</b>	<b>8.8</b>
Anti-Infectives	35.8	0.6	-4.4	4.3
Gastro Intestinal	19.3	11.2	9.4	20.7
Vitamins/Minerals/Nutrients	10.8	11.0	10.6	12.1
Pain / Analgesics	10.7	3.9	1.5	3.4
Anti Diabetic	4.6	18.1	11.2	5.0
Gynaec.	3.9	4.8	1.8	9.7

Source: IQVIA, MOFSL

### Exhibit 22: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 23: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Lupin

Lupin's secondary sales grew 9.9% YoY in May'24 vs. 10.9% YoY in Apr'24. Tonact grew strongly at 18.4% YoY for May'24

### Exhibit 24: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>74,997</b>	<b>6.5</b>	<b>100.0</b>	<b>7.8</b>
Gluconorm-G	Anti Diabetic	3,353	9.2	9.9	12.9
Budamate	Respiratory	2,559	14.4	17.7	2.7
Huminsulin	Anti Diabetic	1,979	-6.0	8.2	2.2
Ivabrad	Cardiac	1,478	10.2	56.9	14.0
Rablet-D	Anti Diabetic	1,189	8.0	9.6	6.2
Ajaduo	Cardiac	1,072	-5.6	37.6	2.8
Tonact	Cardiac	1,070	-1.2	12.3	11.4
Bplex Forte	Anti-Infectives	931	3.0	19.4	1.8
Telekast-L	Anti Diabetic	926	-9.5	6.7	-10.1
Signoflam	Pain / Analgesics	880	10.4	9.8	8.0

\*Three-months: Mar-May'24

Source: IQVIA, MOFSL

Better show in Cardiac/Gastro was partly offset by muted show in anti-infectives.


Price/New launches remained key drivers of growth on MAT May'24 basis

### Exhibit 25: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>6.5</b>	<b>7.8</b>	<b>9.9</b>
Cardiac	22.5	11.1	15.5	16.5
Anti Diabetic	20.2	2.2	6.5	7.7
Respiratory	14.7	7.5	6.0	6.6
Gastro Intestinal	8.8	9.1	10.3	14.2
Anti-Infectives	6.8	3.5	-1.6	-0.7
Gynaec.	5.4	4.5	-3.7	1.9


Source: IQVIA, MOFSL

### Exhibit 26: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 27: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



GSK's secondary sales grew 3.8% YoY in May'24 vs. 3.5% YoY in Apr'24. Decline in Ceftum/T-Bact was offset by strong show in Augmentin/Neosprin/Betnov ate-N.

Vaccines/VMN drove the overall growth in May'24.

GSK managed growth through new launches for MAT May'24

## GlaxoSmithKline Pharmaceuticals

### Exhibit 28: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>51,949</b>	<b>0.2</b>	<b>100.0</b>	<b>0.4</b>
Augmentin	Anti-Infectives	8,172	1.0	22.8	2.0
Calpol	Pain / Analgesics	4,596	-6.7	30.6	-13.8
T-Bact	Derma	3,628	-5.2	77.8	-5.6
Betnovate-N	Derma	2,761	0.3	99.8	2.7
Eltroxin	Hormones	2,580	-0.7	22.6	-1.3
Betnovate-C	Derma	2,507	5.9	99.8	17.2
Ceftum	Anti-Infectives	2,192	-31.7	26.7	-22.7
Infanrix Hexa	Vaccines	2,007	14.1	50.0	-3.0
Neosporin	Derma	1,926	21.1	92.9	19.5
Betnesol	Anti-Infectives	1,683	-1.8	86.8	-5.2

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 29: Therapy mix (%)

	Share	MAT growth (%)	3M*	MAT'24
<b>Total</b>	<b>100.0</b>	<b>0.2</b>	<b>0.4</b>	<b>3.8</b>
Derma	28.5	3.0	5.0	4.0
Anti-Infectives	23.5	-7.6	-4.2	-0.3
Vaccines	12.5	20.6	14.1	15.8
Pain / Analgesics	11.6	-7.0	-12.7	-1.5
Hormones	8.2	-1.1	-2.7	-0.2
Vitamins/Minerals/Nutrients	6.1	6.9	8.8	16.9


Source: IQVIA, MOFSL

### Exhibit 30: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 31: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Glenmark Pharma

Glenmark's secondary sales grew 18.9% YoY in May'24 vs. 18.6% YoY in Apr'24. Telma/Candid family exhibited strong growth in May'24.

### Exhibit 32: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>45,703</b>	<b>10.2</b>	<b>100.0</b>	<b>15.9</b>
Telma	Cardiac	4,825	17.3	39.3	29.9
Telma-H	Cardiac	3,680	26.9	40.2	32.7
Telma-Am	Cardiac	3,314	27.3	29.5	33.8
Ascoril-Ls	Respiratory	2,487	1.6	24.5	1.1
Candid	Derma	1,844	14.6	60.5	32.9
Candid-B	Derma	1,571	11.2	82.8	20.7
Alex	Respiratory	1,400	1.4	5.6	-6.1
Ascoril +	Respiratory	1,294	-9.7	5.3	-16.4
Ascoril D Plus	Respiratory	1,171	2.8	4.8	-12.1
Milibact	Anti-Infectives	1048	20.1	10.1	13.8

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 33: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>10.2</b>	<b>15.9</b>	<b>18.9</b>
Cardiac	32.9	24.0	31.1	26.8
Derma	24.4	9.7	15.4	19.7
Respiratory	22.1	3.0	-0.4	4.2
Anti-Infectives	9.2	11.8	16.6	29.0
Anti-Diabetic	5.7	-14.3	-1.0	0.3
Stomatologicals	1.4	2.6	14.5	18.1

Source: IQVIA, MOFSL

### Exhibit 34: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 35: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Dr. Reddy's Laboratories

Secondary sales grew 9.2% YoY in May'24 vs. 9% YoY in Apr'24. Ketorol/Venusia exhibited 43%/33% YoY growth in May'24.

### Exhibit 36: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>63,290</b>	<b>7.1</b>	<b>100.0</b>	<b>9.0</b>
Voveran	Pain / Analgesics	2,543	5.5	87.5	-6.9
Omez	Pain / Analgesics	2,202	9.1	77.0	13.0
Atarax	Cardiac	2,086	6.1	73.3	13.1
Econorm	Gastro Intestinal	1,910	4.4	92.4	3.0
Ketorol	Pain / Analgesics	1,803	20.8	88.3	32.0
Venusia	Gastro Intestinal	1,396	26.3	7.8	30.7
Razo-D	Derma	1,375	-3.2	11.1	-6.7
Zedex	Respiratory	1,291	-7.6	17.7	-9.1
Bro-Zedex	Respiratory	1,269	-4.7	5.2	-9.3
Vantej	Pain / Analgesics	1,181	29.7	26.7	24.9

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 37: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100</b>	<b>7.1</b>	<b>9.0</b>	<b>9.2</b>
Gastro Intestinal	17.4	9.0	7.6	5.8
Respiratory	14.7	5.4	0.9	2.1
Pain / Analgesics	11.5	11.7	11.2	14.0
Cardiac	10.4	-11.9	0.5	3.6
Derma	7.8	15.7	21.4	15.9
Anti Diabetic	6.0	9.2	7.7	4.4

Source: IQVIA, MOFSL

### Exhibit 38: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 39: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Torrent Pharma

Secondary sales grew 9.3% YoY in May'24 vs. 3.9% in Apr'24. Strong traction in Chymoral/ Shelcal/Nikoran in May'24, which was offset by a decline in Nebicard.

Cardiac/Gastro/Anti-diabetic driving the overall growth in Mar'24

Price/New launches growth was offset by a decline in Volumes on MAT May'24 basis.

### Exhibit 40: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>74,837</b>	<b>8.2</b>	<b>100.0</b>	<b>8.0</b>
Shelcal	VMN	4,490	4.3	34.2	7.3
Chymoral	Pain / Analgesics	3,105	14.0	89.4	10.7
Shelcal Xt	VMN	2,243	22.8	17.4	15.2
Nexpro-Rd	Gastro Intestinal	2,106	10.4	25.6	9.5
Nikoran	Cardiac	2,006	13.8	52.5	13.7
Unienzyme	Gastro Intestinal	1,603	10.3	41.4	14.8
Nebicard	Cardiac	1,396	4.5	54.1	-0.7
Losar	Cardiac	1,308	5.1	59.3	8.5
Veloz-D	Gastro Intestinal	1,232	4.2	9.9	4.4
Losar-H	Cardiac	1,184	-0.5	55.9	-1.2

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 41: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>8.2</b>	<b>8.0</b>	<b>9.3</b>
Cardiac	26.7	7.9	9.6	11.2
Gastro Intestinal	17.5	8.0	8.7	13.8
Neuro / Cns	14.6	9.0	6.4	6.6
Vitamins/Minerals/Nutrients	10.2	8.4	8.6	6.5
Anti Diabetic	8.7	13.3	12.4	14.3
Pain / Analgesics	8.4	7.8	6.0	7.9

Source: IQVIA, MOFSL

### Exhibit 42: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 43: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Alembic Pharmaceuticals

### Exhibit 44: Top 10 drugs

Drug	Therapy	MAT May'24			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	May'24
<b>Total</b>		<b>32072</b>	<b>3.1</b>	<b>100.0</b>	<b>1.6</b>	<b>6.8</b>
Azithral	Anti-Infectives	4513	-5.7	31.2	-7.9	14.3
Althrocin	Respiratory	1311	2.0	88.3	6.7	13.1
Wikoryl	Anti-Infectives	1229	-5.5	8.8	-4.3	7.0
Gestofit	Gynae	1039	6.9	11.5	4.7	5.8
Crina-Ncr	Gynae	785	14.8	26.8	15.7	19.0
Brozeet-Ls	Respiratory	744	2.2	7.3	-5.1	-0.5
Richar Cr	VMN	668	2.6	4.3	-0.1	-2.1
Roxid	Anti-Infectives	650	-4.7	93.6	-9.0	6.6
Isofit	Cardiac	633	62.4	5.2	39.4	35.0
Tellzy-Am	Gynae	633	15.0	5.6	13.6	12.5

\* Three-months: Mar-May'24

Source: IQVIA, MOFSL

Alembic's secondary sales grew 6.8% YoY May'24 vs. 3.2% YoY in Apr'24. Azithral/Althrocin/Crina-NCR/Isofit drove the overall YoY growth in May'24.

Strong show in Anti-infective/Gynae/Antidiabetic was offset by underperformance in Respiratory at the therapy level in May'24.


Price growth was supported by new launches on MAT May'24 basis, offset by a decline in volume

### Exhibit 45: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>3.1</b>	<b>1.6</b>	<b>6.8</b>
Anti-Infectives	21.3	-4.8	-6.5	11.3
Cardiac	15.4	5.7	5.9	5.6
Gynaec.	15.0	14.9	12.4	13.2
Respiratory	13.1	-3.1	-8.0	-0.9
Gastro Intestinal	10.5	8.0	7.6	8.4
Anti Diabetic	7.7	5.9	9.6	12.0

Source: IQVIA, MOFSL

### Exhibit 46: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 47: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Ipca Laboratories

Ipca's secondary sales was 5.7% YoY in May'24 vs. flat growth in Apr'24. Strong show in CTD-T/Tfct-Nib was offset by decline in solvin gold/zerodol-P in May'24.

All therapies outperformed, except PAIN therapy, in May'24.

Price and volume were key growth drivers on MAT basis

### Exhibit 48: Top 10 drugs

Drug	Therapy	Value (INR m)	Growth (%)	MAT May'24		Growth (%)	
				Market share (%)	Last 3M	May'24	
<b>Total</b>		<b>42958</b>	<b>10.6</b>	<b>100.0</b>	<b>6.5</b>	<b>5.7</b>	
Zerodol-Sp	Pain / Analgesics	5442	16.9	60.6	5.8	6.1	
Zerodol-P	Pain / Analgesics	2777	3.2	48.7	-3.7	-3.1	
Hcqs	Anti Malarials	1834	1.0	82.6	5.3	5.4	
Folitrax	Anti-Neoplastics	1286	12.6	84.9	7.0	1.5	
Zerodol-Th	Pain / Analgesics	1189	6.7	57.1	1.7	4.9	
Ctd-T	Cardiac	1029	27.0	19.0	24.6	19.2	
Solvin Cold	Anti-Infectives	893	-3.7	6.5	-10.6	-8.0	
Ctd	Cardiac	743	4.8	97.7	5.5	5.9	
Tfct-Nib	Gastro Intestinal	683	20.7	22.3	12.6	10.9	
Pacimol	Pain / Analgesics	661	7.1	3.3	-2.4	8.8	

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 49: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>10.6</b>	<b>6.5</b>	<b>5.7</b>
Pain / Analgesics	39.2	10.6	3.1	3.9
Cardiac	12.8	12.9	12.2	7.3
Anti-Infectives	7.6	3.2	1.9	6.2
Derma	5.6	19.8	16.9	8.7
Antineoplast/Immunomodulator	5.4	15.5	10.6	6.4
Gastro Intestinal	5.0	4.6	6.6	8.1

Source: IQVIA, MOFSL

### Exhibit 50: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 51: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Eris Lifesciences

Eris's secondary sales grew 10.6% YoY in May'24 vs. 15.9% in Apr'24. Cyblex Glimisave-Mv were outperforming brands in May'24.

Derma/VMN outperformed for May'24.

Growth was driven by new launches and price hikes on MAT basis, which was offset by a decline in volumes.

### Exhibit 52: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>23363</b>	<b>8.9</b>	<b>100.0</b>	<b>11.2</b>
Renerve Plus	Neuro	1403	2.4	11.2	2.7
Glimisave Mv	Anti Diabetic	1314	14.7	10.2	13.2
Glimisave-M	Anti Diabetic	1028	0.2	3.0	-3.0
Zomelis-Met	Anti Diabetic	492	2.9	5.4	0.0
Remylin D	VMN	458	7.5	10.0	2.0
Eritel Ln	Cardiac	451	14.1	8.9	10.6
Cyblex Mv	Cardiac	397	17.8	49.7	24.1
Eritel Ch	Anti Diabetic	392	4.6	7.3	3.3
Ln Beta	Cardiac	327	21.7	69.2	11.8
Lnblock	Cardiac	309	7.4	4.1	2.3

\*Three-months: Feb-Apr'24


Source: IQVIA, MOFSL

### Exhibit 53: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>8.9</b>	<b>11.2</b>	<b>10.6</b>
Anti-Diabetic	28.9	12.2	11.4	11.6
Cardiac	18.5	8.7	5.1	4.7
Vitamins/Minerals/Nutrients	15.9	14.9	21.8	21.4
Derma	13.6	-4.1	15.3	16.3
Gynaec.	6.6	14.0	4.1	-1.0
Neuro / Cns	6.3	7.0	4.4	5.4

Source: IQVIA, MOFSL

### Exhibit 54: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 55: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Abbott India

Abbott's secondary sales increased 9.2% YoY in May'24 vs. 9.3% in Apr'24. Udiliv/Cremaffin/Rybelsus outperformed among top 10 brands for May'24, offset by decline in Novomix.

Anti-infective drove the growth in May'24.

Price/New launches led growth on MAT May'24 basis

### Exhibit 56: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>136065</b>	<b>7.9</b>	<b>100.0</b>	<b>6.3</b>
Mixtard	Anti Diabetic	8486	-3.1	35.3	-5.8
Thyronorm	Hormones	6242	7.7	54.6	5.5
Udiliv	Gastro Intestinal	5822	23.5	51.2	24.7
Ryzodeg	Anti Diabetic	5498	18.6	22.9	14.2
Duphaston	Gynae	3929	5.6	32.5	-1.4
Novomix	Anti Diabetic	3785	-13.6	15.7	-11.3
Cremaffin Plus	Gastro Intestinal	3234	34.0	49.3	37.4
Duphalac	Neuro / Cns	3125	6.3	51.7	8.4
Rybelsus	Anti Diabetic	3069	99.6	92.2	43.9
Vertin	Gastro Intestinal	2958	3.9	66.0	-4.1

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 57: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>7.9</b>	<b>6.3</b>	<b>9.2</b>
Anti Diabetic	23.8	7.4	3.5	4.2
Gastro Intestinal	14.8	9.8	8.8	8.3
Vitamins/Minerals/Nutrients	9.0	11.8	12.0	9.4
Anti-Infectives	8.6	2.0	-2.7	16.7
Neuro / Cns	7.0	0.2	-2.3	-3.5
Hormones	6.8	13.4	12.0	8.9

Source: IQVIA, MOFSL

### Exhibit 58: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 59: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Mankind Pharma

Mankind's secondary sales grew 11.1% YoY in May'24 vs. 11.8% YoY in Apr'24. Amlokind/Dydroboon/Manforce led overall YoY growth in May'24.

Anti-diabetes/GI/Cardiac grew better than respiratory for May'24

Price/New launches led overall YoY growth for MAT May'24

### Exhibit 60: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>97,518</b>	<b>7.8</b>	<b>100.0</b>	<b>9.0</b>
Manforce	Sex Stimulants / Rejuvenators	5,028	11.6	73.1	12.7
Moxikind-Cv	Anti-Infectives	3,868	6.7	12.2	6.1
Unwanted-Kit	Gynae	2,510	10.7	52.8	7.7
Amlokind-At	Cardiac	2,495	23.4	35.7	24.1
Prega News	Gynae	2,251	4.5	83.7	-0.5
Dydroboon	Gynae	2,154	4.4	17.8	16.6
Gudcef	Anti-Infectives	2,026	5.5	17.0	2.4
Candiforce	Anti-Infectives	1,967	6.9	20.7	7.3
Glimestar-M	Anti Diabetic	1,940	12.2	5.7	12.2
Nurokind-Gold	VMN	1,594	12.3	8.1	11.5
					15.0

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 61: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>7.8</b>	<b>9.0</b>	<b>11.1</b>
Anti-Infectives	15.1	6.1	2.3	8.0
Cardiac	14.2	18.6	22.3	19.0
Gastro Intestinal	10.7	10.0	15.1	22.5
Anti Diabetic	8.7	14.4	16.9	14.3
Vitamins/Minerals/Nutrients	8.4	6.2	9.7	12.2
Respiratory	8.2	-7.1	-12.9	-11.1

Source: IQVIA, MOFSL

### Exhibit 62: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 63: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Macleods Pharma

Macleods's secondary sales grew 15.9% YoY in May'24 vs. 10% YoY in Apr'24. Meromac/Megalis/Geminor grew 45%/19%/21% YoY in May'24.

### Exhibit 64: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>73,873</b>	<b>9.4</b>	<b>100.0</b>	<b>9.6</b>
Meromac	Hormones	2,302	37.4	15.3	44.9
Thyrox	Anti-Infectives	2,244	3.6	19.6	12.2
Omnacortil	Derma	1,951	16.3	60.6	12.0
Panderm ++	Anti-Infectives	1,912	-3.7	51.8	-3.0
Defcort	Respiratory	1,463	9.7	54.4	9.9
Megalis	Anti-Infectives	1,378	23.3	60.0	24.6
It-Mac	Sex Stimulants / Rejuvenators	1,364	-3.4	14.4	-4.3
Sensiclav	Anti-Infectives	1,312	3.8	3.0	6.8
Geminor-M	Anti Diabetic	1,311	10.5	3.9	18.2
Tazomac	Anti-Infectives	1152	14.9	13.0	8.8

\*Three-months: Mar-May'24


Source: IQVIA, MOFSL

### Exhibit 65: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>9.4</b>	<b>9.6</b>	<b>15.9</b>
Anti-Infectives	29.4	11.1	11.7	24.1
Cardiac	12.4	12.6	12.2	12.2
Respiratory	9.2	8.8	2.2	12.1
Hormones	8.7	9.4	10.4	15.1
Pain / Analgesics	8.2	9.7	11.9	15.6
Anti Diabetic	6.0	12.5	13.4	14.0

Source: IQVIA, MOFSL

### Exhibit 66: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 67: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## Ajanta Pharma

Ajanta's secondary sales grew 12.3% YoY in May'24 vs. 12.3% YoY in Apr'24. Melacare/Met XL/Atrofit outperformed in top 10 brands category for May'24.

### Exhibit 68: Top 10 drugs

Drug	Therapy	MAT May'24		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M
<b>Total</b>		<b>16680</b>	<b>9.0</b>	<b>100.0</b>	<b>10.4</b>
Met XI	Cardiac	1585	-7.6	23.0	7.6
Melacare	Derma	824	7.8	24.8	18.4
Feburic	Pain / Analgesics	780	4.8	18.8	0.3
Atorfit-Cv	Cardiac	743	7.1	19.8	11.1
Cinod	Cardiac	465	17.5	6.2	24.1
Met XI Trio	Cardiac	414	20.6	28.7	29.2
Met XI Am	Cardiac	395	2.5	13.1	6.4
Rosufit-Cv	Cardiac	362	6.6	11.7	10.6
Olopat	Cardiac	278	8.0	38.7	2.4
Cilamet-XI	Anti-Infectives	277	13.9	28.1	10.9

\*Three-months: Mar-May'24

Source: IQVIA, MOFSL

Cardiac/Derma did better than Ophthal/pain for May'24.


Price/New product launches led growth on MAT May'24 basis

### Exhibit 69: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>9.0</b>	<b>10.4</b>	<b>12.3</b>
Cardiac	35.0	4.6	11.1	15.4
Ophthal / Otologicals	28.4	10.0	5.3	7.3
Derma	21.0	17.2	21.2	19.1
Pain / Analgesics	7.8	8.8	3.2	2.9
Anti-Diabetic	2.5	4.7	3.1	9.9
Respiratory	1.7	10.5	10.7	14.1


Source: IQVIA, MOFSL

### Exhibit 70: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

### Exhibit 71: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFSL



## JB Chemicals and Pharmaceuticals

### Exhibit 72: Top 10 drugs

Secondary sales grew 13.1% YoY in May'24 vs. 14.3% in Apr'24. Cilacar/Nicardia grew strongly in May'24, offset by decline in Azmarda and Nevanac.

Cardiac/Gynaec/derma therapies were strong for May'24 offset by double digit decline in Ophthal

Price and volume growth were key drivers for growth on MAT basis

Drug	Therapy	MAT May'24		Growth (%)		
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	May'24
<b>Total</b>		<b>25124</b>	<b>10.2</b>	<b>100.0</b>	<b>10.8</b>	<b>13.1</b>
Cilacar	Cardiac	4060	20.8	54.2	26.3	29.9
Rantac	Gastro Intestinal	3659	2.3	40.6	-5.9	-9.0
Metrogyl	Anti-Parasitic	2119	9.1	80.3	10.6	8.0
Cilacar-T	Cardiac	1838	27.7	36.4	39.9	41.2
Nicardia	Cardiac	1788	16.7	91.8	16.9	16.4
Sporlac	Gastro Intestinal	993	7.3	59.8	1.4	20.9
Azmarda	Cardiac	701	-39.5	11.4	-38.9	-30.3
Vigamox	Anti-Parasitic	602	2.1	22.9	-4.7	-4.3
Cilacar-M	Cardiac	388	20.0	39.4	26.4	30.8
Nevanac	Ophthalmic	323	-10.4	19.6	-8.5	-28.9

\*Three-months: Mar-May'24


Source: IQVIA, MOFS

### Exhibit 73: Therapy mix (%)

	Share	MAT growth (%)	3M*	May'24
<b>Total</b>	<b>100.0</b>	<b>10.2</b>	<b>10.8</b>	<b>13.1</b>
Cardiac	42.3	14.5	20.5	23.9
Gastro Intestinal	26.5	10.2	4.6	7.2
Anti-Parasitic	8.1	9.3	10.7	8.0
Ophthal / Otologicals	7.8	-6.3	-9.7	-18.1
Gynaec.	4.3	20.2	18.0	26.5
Derma	2.4	8.3	15.4	28.8


Source: IQVIA, MOFS

### Exhibit 74: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFS

### Exhibit 75: Growth distribution (%) (MAT May'24)



Source: IQVIA, MOFS

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including Investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dp@motilaloswal.com](mailto:dp@motilaloswal.com).